BID News and Press, Sotheby's From 02/22/20

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...

Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

Sotheby's (NYSE: BID ) appoints Charles Stewart as the company's new CEO to take over immediately. More news on: Sotheby's, Consumer stocks news, Read more ...

Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...

NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Sotheby's announced today that ownership of the Company has officially transferred to Patrick Drahi.  The acquisition, which was announced in June of this year, returns the 275-year-old firm to private ownership after 31 years on the New York S...

NEW YORK , Sept. 26, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Las Vegas Sands Corp. (NYSE: LVS) will replace Nektar Therapeutics (NASD: NKTR) in the S&P 500, and Nektar Therapeuti...

Las Vegas Sands (NYSE: LVS ) is up 4.5% alongside news that it's joining the S&P 500 index . More news on: Las Vegas Sands Corp., Nektar Therapeutics, Sotheby's, Stocks on the move, Consumer stocks news, Healthcare stocks news Read more ...